Ann: Appendix 4E and 2019 Annual Report, page-3

SYC's statement on Page 5. A couple of really interesting points. Firstly, you have to imagine there's going to be some very positive announcements over the next few months with a statement like this:

"Excellent progress in the HER2 negative breast cancer, relapsed and refractory acute myeloid leukemia and recurrent or platinum resistant ovarian cancer trials."

This part is also telling, particularly with 'regulatory and commercial inflection points'.  The points come to mind are approvals and partnering?

"The coming year will see a number of important clinical, regulatory and commercial inflection points in our efforts to bring important new cancer therapies to global markets. We have an extensive program to engage with the local and international investor and medical communities to highlight the potential of our assets and ensure the market can accurately measure our progress and value in a global context."